Eisai slashing Aricept prices to foster Asian sales

Eisai has become the latest drugmaker to cut prices in an effort to push sales in emerging markets. On the heels of similar moves by GlaxoSmithKline and Sanofi-Aventis, the Japanese company is cutting prices on its Alzheimer's remedy Aricept in at least six Asian countries.

The idea is to ratchet up demand by opening the door to less prosperous patients, says Eisai's Yasushi Okada, who heads up operations in Asia, Oceania and the Middle East. "With the current prices, only a part of the wealthy people can afford to buy our products," Okada tells Bloomberg. "I want to increase the patient accessibility of the medicines in Asia."

Okada tells the news service that he expects growth in sales volume to outweigh the price cuts, delivering overall sales growth. And that's the aim of GSK and Sanofi as well. GSK has announced major price cuts in emerging markets, with prices tiered according to the target population.

In some GSK markets, prices will be less than two-thirds of those in Europe; in the 50 poorest nations, they'll be 25 percent of Western prices, Bloomberg points out. Meanwhile, Sanofi announced early this year that it would follow suit, cutting prices in Southeast Asia by as much as half.

Okada wouldn't say just how much Eisai plans to cut the price tags on Aricept. In the coming quarters, however, we'll be able to see how the cuts affect sales in those markets. For 2008, Aricept's global revenues amounted to $3 billion; the company loses patent protection in the U.S. in November, so it stands to lose revenues here to generic competition. All the more reason to grow sales in emerging markets.

- read the Bloomberg story

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.